Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis.
暂无分享,去创建一个
G. Niccoli | F. Crea | M. D. Del Buono | G. Minotti | M. Galli | N. Aspromonte | R. Montone | M. Lombardi | G. Zoccai | G. Vescovo | M. Camilli
[1] Agnes Y. Y. Lee,et al. Anticoagulant Therapy for Venous Thromboembolism in Cancer. , 2020, The New England journal of medicine.
[2] A. Torbicki,et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.
[3] M. Humbert,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .
[4] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[5] K. Porter,et al. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer – A real world experience , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[6] M. Murad,et al. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. , 2019, Mayo Clinic proceedings.
[7] C. Combescure,et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis , 2019, PloS one.
[8] Joshua D. Brown,et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. , 2019, The Lancet. Haematology.
[9] G. Lyman,et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.
[10] A. H. Mohammed,et al. Correction to: Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis , 2018, Journal of Thrombosis and Thrombolysis.
[11] H. Badreldin,et al. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis , 2018, Journal of Thrombosis and Thrombolysis.
[12] G. Lyman,et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Khorana,et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer , 2018, American journal of hematology.
[14] G. Raskob,et al. Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.
[15] C. Loprinzi,et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism , 2017, Thrombosis and Haemostasis.
[16] A. Khorana,et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer‐associated thrombosis , 2017, Research and practice in thrombosis and haemostasis.
[17] W. Leung,et al. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management , 2017, World journal of gastroenterology.
[18] N. Brunetti,et al. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. , 2017, International journal of cardiology.
[19] S. Schulman,et al. Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.
[20] L. Robertson,et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. , 2015, The Cochrane database of systematic reviews.
[21] F. Violi,et al. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[22] J. Weitz,et al. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. , 2014, Blood.
[23] Alexander Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[24] E. Kuipers,et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. , 2013, Gastroenterology.
[25] Carol Lefebvre,et al. How to identify randomized controlled trials in MEDLINE: ten years on. , 2006, Journal of the Medical Library Association : JMLA.
[26] H. Chew,et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.
[27] Paolo Prandoni,et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.